Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
158 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
001696-C
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
Recruitment has not started
3-120 Years
NCI
Benign Neoplasm
001560-DC
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
Participants currently recruited/enrolled
3-99 Years
NIDCD
Laryngeal Neoplasm
18-DC-0051
Biospecimen Procurement for the Study of Head and Neck Disorders
Participants currently recruited/enrolled
3-120 Years
NCI
Laryngeal Neoplasm
11-C-0190
Collection of Tissue Blocks or Slides from Patients with Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Benign Neoplasm
09-C-0242
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Participants currently recruited/enrolled
4-125 Years
NCI
Benign Neoplasm
00-CH-0160
Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue
Completed Study; data analyses ongoing
3-70 Years
NICHD
Benign Neoplasm
002056-C
Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
Recruitment has not started
18-120 Years
NCI
Neoplasm
001961-C
A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001924-C
A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors
Recruitment has not started
18-120 Years
NCI
Neoplasm
001920-C
A ComboMATCH Treatment Trial: FOLFOX In Combination With Binimetinib As 2nd Line Therapy For Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001837-C
A Phase I Study to Establish the Feasibility of Enolen(TM) for the Local Delivery of Enzalutamide in Patients with Prostate Cancer
Participants currently recruited/enrolled
21-120 Years
NCI
Neoplasm
001784-C
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Recruitment has not started
18-120 Years
NCI
Neoplasm
001783-C
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cel
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001778-C
A Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001776-C
A Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001732-C
A Phase 1 Study of the Polymerase Theta (POL-Theta) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001715-C
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associ
Participants currently recruited/enrolled
12-120 Years
NCI
Neoplasm
001695-C
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (anti-VISTA) as Monotherapy and in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Recruitment has not started
18-120 Years
NCI
Neoplasm
001657-C
Phase 1 Umbrella Trial of Erlotinib In Combination with Select Tyrosine Kinase Inhibitors In Adult Patients with Advanced Solid Tumors
Recruitment has not started
18-120 Years
NCI
Neoplasm
001636-CC
A Pilot Study of a Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
Participants currently recruited/enrolled
18-100 Years
CC
Neoplasm
001608-N
Pre-operative vs. Post-operative Stereotactic Radiosurgery for Operative Metastatic Brain Tumors
Participants currently recruited/enrolled
18-99 Years
NINDS
Neoplasm
001572-C
A Phase II Study of Bevacizumab in Adults with Recurrent Respiratory Papillomatosis (RRP)
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001569-C
A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
Recruitment has not started
18-100 Years
NCI
Neoplasm
001567-C
Observational Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy
Participants currently recruited/enrolled
35-120 Years
NCI
Neoplasm
001554-C
Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Recruitment has not started
12-120 Years
NCI
Neoplasm
001547-C
A First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001544-C
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with Entinostat and Nivolumab as Adjuvant Therapy following Chemoradiation Therapy with or without Surgery for Locally Advanced Esophageal Cancer
Clinical hold/Recruitment or enrollment suspended
18-120 Years
NCI
Neoplasm
001534-C
Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors containing MYC or MYCN Amplifications
Participants currently recruited/enrolled
18-120 Years
NCI
Benign
000954-C
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing Cancer
No longer recruiting/follow-up only
18-120 Years
NCI
Neoplasm
000732-C
A Long-Term Follow-Up Study of Patients Who Received VOR33
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000697-H
U01 Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE)
Participants currently recruited/enrolled
18-65 Years
NHLBI
Neoplasm
000678-C
Rare Tumors and Cancer Predisposition in Individuals and Families
Participants currently recruited/enrolled
0-125 Years
NCI
Neoplasm
000666-C
A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Participants currently recruited/enrolled
18-100 Years
NCI
Neoplasm
000661-C
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
Participants currently recruited/enrolled
0-120 Years
NCI
Neoplasm
000611-C
A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
000580-C
A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2(alpha) Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinom
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000491-C
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000489-C
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
Participants currently recruited/enrolled
12-120 Years
NCI
Neoplasm
000473-C
A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000464-H
Evaluation of Clonal Hematopoiesis in Patients with Sickle Cell Disease Receiving Curative Therapies
Enrolling by Invitation
4-125 Years
NHLBI
Neoplasm
000359-C
Phase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignancies
Participants currently recruited/enrolled
12-85 Years
NCI
Neoplasm
000356-C
A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
000307-C
Phase II Study Evaluating the Efficacy of M9241 in Combination with Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects with Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000305-C
Exploratory Phase II Study of LAnreotide in Unresectable or Metastatic Pheochromocytoma / PARAganglioma
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
000302-C
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000274-C
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Clinical hold/Recruitment or enrollment suspended
18-125 Years
NCI
Neoplasm
000237-C
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000123-CC
Evaluation of Atherosclerotic Plaques in Abdominal CT Studies
No longer recruiting/follow-up only
30-90 Years
CC
Neoplasm
000103-C
A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000067-C
Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy
Completed Study; data analyses ongoing
2-125 Years
NCI
Neoplasm
000030-C
Phase 2 Study of Bintrafusp alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
22-C-0005
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
21-I-0029
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Participants currently recruited/enrolled
3-125 Years
NIAID
Benign
21-C-0032
GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure
Participants currently recruited/enrolled
0-40 Years
NCI
Neoplasm
21-C-0022
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR(TM) T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Participants currently recruited/enrolled
10-75 Years
NCI
Neoplasm
21-C-0006
Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
21-C-0001
A Phase I/II Study of M9241 with Docetaxel and Abiraterone in Adults with Metastatic Castration Sensitive and M9241 with Docetaxel in Castration Resistant Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
20-N-0019
The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease
Participants currently recruited/enrolled
18-125 Years
NINDS
Benign
20-C-0161
Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Participants currently recruited/enrolled
6-125 Years
NCI
Neoplasm
20-C-0150
Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
20-C-0130
A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
Completed Study; data analyses ongoing
12-120 Years
NCI
Neoplasm
20-C-0121
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
20-C-0069
A First-In-Human Phase I Single-Agent Dose-Escalation and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
20-C-0051
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Enrolling by Invitation
18-120 Years
NCI
Neoplasm
20-C-0041
Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Enrolling by Invitation
1-125 Years
NCI
Neoplasm
20-C-0028
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Participants currently recruited/enrolled
3-35 Years
NCI
Neoplasm
20-C-0024
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.
Completed Study; data analyses ongoing
18-120 Years
NCI
Neoplasm
20-C-0023
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors
Participants currently recruited/enrolled
12-120 Years
NCI
Neoplasm
20-C-0022
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
20-C-0012
A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
19-C-0138
Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
19-C-0128
A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
19-C-0117
A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing Cancer
No longer recruiting/follow-up only
18-120 Years
NCI
Neoplasm
19-C-0112
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Participants currently recruited/enrolled
12-120 Years
NCI
Neoplasm
19-C-0040
Natural History Study of Men at High Genetic Risk for Prostate Cancer
Participants currently recruited/enrolled
30-75 Years
NCI
Neoplasm
19-C-0016
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
Participants currently recruited/enrolled
0-125 Years
NCI
Neoplasm
18-N-0133
Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery
Participants currently recruited/enrolled
18-85 Years
NINDS
Neoplasm
18-CH-0031
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Clinical hold/Recruitment or enrollment suspended
7-70 Years
NIDDK
Neoplasm
18-C-0093
Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
Completed Study; data analyses ongoing
3-59 Years
NCI
Benign
18-C-0078
A Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, N-803 and Epacadostat (QuEST1)
No longer recruiting/follow-up only
18-120 Years
NCI
Neoplasm
18-C-0058
A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
18-C-0028
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
18-C-0014
Phase I Trial of 5-aza-4'-thio-2'-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
18-C-0008
Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
17-C-0158
A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer Patients
Enrolling by Invitation
18-120 Years
NCI
Neoplasm
17-C-0157
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
17-C-0156
Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
17-C-0153
Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior Radiotherapy
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
17-C-0109
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Enrolling by Invitation
18-125 Years
NCI
Neoplasm
17-C-0092
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
17-C-0089
Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate Cancer
Enrolling by Invitation
18-125 Years
NCI
Neoplasm
17-C-0087
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
17-C-0044
Prospective Evaluation and Molecular Profiling in Patients with Gastric Tumors
Participants currently recruited/enrolled
2-125 Years
NCI
Neoplasm
17-C-0043
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
Participants currently recruited/enrolled
2-125 Years
NCI
Neoplasm
16-N-0041
Tumor Related Epilepsy
Participants currently recruited/enrolled
8-99 Years
NINDS
Neoplasm
16-CC-0098
Pilot Study of Ultrasound Guided Focal Thermal Ablation of Prostate Cancer
Clinical hold/Recruitment or enrollment suspended
18-100 Years
CC
Neoplasm
16-CC-0049
A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment with Transarterial Embolization (TAE) Alone or Combined with Thermal Ablation
Completed Study; data analyses ongoing
18-100 Years
CC
Neoplasm
16-C-0171
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
16-C-0151
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0121
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0107
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
16-C-0097
Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma
Completed Study; data analyses ongoing
2-21 Years
NCI
Neoplasm
16-C-0092
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0087
Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0048
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0034
A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
15-H-0172
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
No longer recruiting/follow-up only
18-125 Years
NHLBI
Neoplasm
15-C-0200
Molecular Analysis for Therapy Choice (MATCH) (EAY131)
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
15-C-0160
A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
15-C-0150
A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
15-C-0145
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
15-C-0116
Phase I Trial of 4'-thio-2'-deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
Clinical hold/Recruitment or enrollment suspended
18-120 Years
NCI
Neoplasm
15-C-0086
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients with Refractory Solid Tumors
Participants currently recruited/enrolled
12-120 Years
NCI
Neoplasm
15-C-0076
A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
15-C-0075
A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
14-C-0163
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis
Completed Study; data analyses ongoing
10-125 Years
NCI
Benign
14-C-0161
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
14-C-0128
Collection of Pharmacokinetic and Probe Substrate Samples from Participants with Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
Enrolling by Invitation
2-125 Years
NCI
Neoplasm
13-C-0202
Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing Cancers
Participants currently recruited/enrolled
2-125 Years
NCI
Neoplasm
13-C-0176
Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors
Clinical hold/Recruitment or enrollment suspended
2-125 Years
NCI
Neoplasm
13-C-0119
Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
13-C-0105
Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Completed Study; data analyses ongoing
18-120 Years
NCI
Neoplasm
12-H-0064
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Participants currently recruited/enrolled
4-75 Years
NHLBI
Neoplasm
12-H-0035
A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p Deletion
No longer recruiting/follow-up only
18-125 Years
NHLBI
Neoplasm
12-C-0205
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
12-C-0118
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
No longer recruiting/follow-up only
18-100 Years
NCI
Neoplasm
12-C-0081
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
12-C-0079
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
12-C-0066
Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
11-CC-0152
The Natural History of Liver Disease in a Cohort of Participants with Hepatitis B and/or Hepatitis C with or without HIV Infection
Completed Study; data analyses ongoing
18-99 Years
CC
Neoplasm
11-C-0255
Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome
Participants currently recruited/enrolled
0-125 Years
NCI
Neoplasm
11-C-0247
A Randomized Phase II Study of Tecemotide in Combination with Standard Androgen Deprivation Therapy and Radiation Therapy for untreated, intermediate and High Risk Prostate Cancer Patients
Completed Study; data analyses ongoing
18-100 Years
NCI
Neoplasm
11-C-0140
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
11-C-0061
Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
No longer recruiting/follow-up only
18-120 Years
NCI
Neoplasm
10-CC-0217
A Comparison of Methods for Assisting Needle Angle Selection During Image-Guided Tissue Biopsy
Completed Study; data analyses ongoing
18-125 Years
CC
Neoplasm
10-C-0056
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
09-C-0139
A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
09-C-0053
Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Don
Enrolling by Invitation
1-125 Years
NCI
Neoplasm
08-C-0130
A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
Completed Study; data analyses ongoing
0-21 Years
NCI
Benign
07-C-0100
Collection of Blood from Patients with Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
06-C-0213
Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
Participants currently recruited/enrolled
0-125 Years
NCI
Neoplasm
06-C-0134
Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1
Completed Study; data analyses ongoing
20-99 Years
NCI
Benign
05-CC-0091
Electromagnetic Tracking of Devices During Interventional Procedures
Enrolling by Invitation
18-120 Years
CC
Neoplasm
04-H-0012
Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples from Patients with Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members
Participants currently recruited/enrolled
2-100 Years
NHLBI
Neoplasm
04-C-0232
A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
04-C-0165
Data Collection, Clinical Care and Interventions in CCR, NCI
Enrolling by Invitation
0-120 Years
NCI
Neoplasm
03-C-0066
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
Participants currently recruited/enrolled
2-125 Years
NCI
Benign
02-I-0286
Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome
Participants currently recruited/enrolled
2-125 Years
NIAID
Neoplasm
02-C-0159
Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts
Participants currently recruited/enrolled
2-125 Years
NCI
Neoplasm
99-C-0099
Examination of Clinical and Laboratory Abnormalities in Patients with Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
No longer recruiting/follow-up only
0-125 Years
NCI
Neoplasm
97-CH-0076
A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders
Participants currently recruited/enrolled
3-70 Years
NICHD
Neoplasm
97-C-0147
Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Diseases
Participants currently recruited/enrolled
2-125 Years
NCI
Neoplasm
94-HG-0132
The Phenotype and Etiology of Proteus Syndrome
Participants currently recruited/enrolled
0-99 Years
NHGRI
Benign
93-I-0063
Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells
Participants currently recruited/enrolled
0-99 Years
NIAID
Benign
78-C-0039
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
No longer recruiting/follow-up only
0-125 Years
NCI
Neoplasm